ブリンシドフォビル (Synonyms: Brincidofovir; CMX001; HDP-CDV)

Name: Brincidofovir
Brand: MedChemExpress
SKU: HY-14532
Rating: 5.0 (5 reviews)

製品番号: HY-14532 純度: 99.72%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

ブリンシドフォビル 構造式

CAS 番号 : 444805-28-1

容量	価格（税別）	在庫状況	数量
1 mg	$60	在庫あり	Estimated Time of Arrival: December 31
5 mg	$140	在庫あり	Estimated Time of Arrival: December 31
10 mg	$210	在庫あり	Estimated Time of Arrival: December 31
25 mg	$420	在庫あり	Estimated Time of Arrival: December 31
50 mg	$630	在庫あり	Estimated Time of Arrival: December 31
100 mg	$945	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Other Forms of Brincidofovir:

Brincidofovir-d₆ お問い合わせ

顧客検証

HSV アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

HSV-1 HSV-2 HSV

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

EC50: 5.5 nM (anti-CMV, in PDA at 7 dpi)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	20.07 3 Compound: BCV; HDP-CV, CMX001	Cytotoxicity against human A549 cells incubated for 72 hrs by neutral red based spectrophotometric analysis Cytotoxicity against human A549 cells incubated for 72 hrs by neutral red based spectrophotometric analysis	[PMID: 37390509]
BSC-1	CC₅₀	25.3 3 Compound: 1, HDP-CDV	Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay	[PMID: 21493074]
BSC-1	EC₅₀	0.125 3 Compound: 1, HDP-CDV	Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay	[PMID: 21493074]
BSC-1	EC₅₀	0.125 3 Compound: 1, HDP-CDV	Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay	[PMID: 21493074]
BSC-1	CC₅₀	25.3 3 Compound: 1, HDP-CDV	Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay	[PMID: 21493074]
BSC-1	CC₅₀	25.3 3 Compound: 1, HDP-CDV	Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay	[PMID: 21493074]
BSC-1	EC₅₀	0.125 3 Compound: 1, HDP-CDV	Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.08 3 Compound: 1, HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.9 1 Compound: HDP (S)-HPMPC	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HFF	CC₅₀	25 3 Compound: 1, HDP-CDV	Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay	[PMID: 21493074]
HFF	CC₅₀	31 3 Compound: HDP-CDV	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	EC₅₀	0.13 3 Compound: CMX001	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	CC₅₀	31 3 Compound: HDP-CDV	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	CC₅₀	42 3 Compound: CMX001	Cytotoxicity against HFF cells after 7 days by neutral red assay Cytotoxicity against HFF cells after 7 days by neutral red assay	[PMID: 17724153]
HFF	EC₅₀	0.14 3 Compound: CMX001	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	CC₅₀	25 3 Compound: 1, HDP-CDV	Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay	[PMID: 21493074]
HFF	CC₅₀	42 3 Compound: CMX001	Cytotoxicity against HFF cells after 7 days by neutral red assay Cytotoxicity against HFF cells after 7 days by neutral red assay	[PMID: 17724153]
HFF	EC₅₀	0.2 3 Compound: 1, HDP-CDV	Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.0009 3 Compound: HDP (S)-HPMPC	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HFF	EC₅₀	0.24 3 Compound: CMX001	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.2 3 Compound: 1, HDP-CDV	Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.06 3 Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	0.6 3 Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.6 3 Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.08 3 Compound: 1, HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.24 3 Compound: CMX001	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.8 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.08 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	0.06 3 Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	1.1 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.13 3 Compound: CMX001	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.8 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	CC₅₀	25 3 Compound: 1, HDP-CDV	Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay	[PMID: 21493074]
HFF	EC₅₀	0.14 3 Compound: CMX001	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	CC₅₀	31 3 Compound: HDP-CDV	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	EC₅₀	0.14 3 Compound: CMX001	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.08 3 Compound: 1, HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.2 3 Compound: 1, HDP-CDV	Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	CC₅₀	42 3 Compound: CMX001	Cytotoxicity against HFF cells after 7 days by neutral red assay Cytotoxicity against HFF cells after 7 days by neutral red assay	[PMID: 17724153]
HFF	EC₅₀	0.24 3 Compound: CMX001	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.08 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	0.6 3 Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	1.1 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.8 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.13 3 Compound: CMX001	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	1.1 3 Compound: HDP-CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
Vero	CC₅₀	13.87 3 Compound: BCV; HDP-CV, CMX001	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by neutral red based spectrophotometric analysis Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by neutral red based spectrophotometric analysis	[PMID: 37390509]

体内実験

Brincidofovir (BCV) (20 mg/kg; p.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24) extends survival in immune-deficient BALB/c nu/nu mice following lethal challenge with IHD-J-Luc VACV^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nu/nu mice (infected with IHD-J-Luc VACV)^[3]
Dosage:	20 mg/kg
Administration:	P.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24
Result:	On days 1, 3, and 5 maintained their weights initially but started to lose weight beginning on day 9 and succumbed between days 24 and 29 postchallenge.

臨床実験

分子量

561.69

分子式

C₂₇H₅₂N₃O₇P

CAS 番号

444805-28-1

Appearance

Solid

Color

White to off-white

SMILES

NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

0.1 M NaOH : 50 mg/mL (89.02 mM; Need ultrasonic)

DMSO : 1 mg/mL (1.78 mM; adjust pH to 8 with NaOH and heat to 50°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7803 mL	8.9017 mL	17.8034 mL
5 mM	0.3561 mL	1.7803 mL	3.5607 mL
10 mM	0.1780 mL	0.8902 mL	1.7803 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

純度とドキュメンテーション

純度: 99.72%

Select Batch:

データシート (270 KB) SDS (394 KB)

COA (241 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. [Content Brief]

[2]. Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40(6):e364-e368. [Content Brief]

[3]. Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89(6):3295-3307. [Content Brief]

[4]. Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9(11):320. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / 0.1 M NaOH	1 mM	1.7803 mL	8.9017 mL	17.8034 mL	44.5085 mL
0.1 M NaOH	5 mM	0.3561 mL	1.7803 mL	3.5607 mL	8.9017 mL
	10 mM	0.1780 mL	0.8902 mL	1.7803 mL	4.4509 mL
	15 mM	0.1187 mL	0.5934 mL	1.1869 mL	2.9672 mL
	20 mM	0.0890 mL	0.4451 mL	0.8902 mL	2.2254 mL
	25 mM	0.0712 mL	0.3561 mL	0.7121 mL	1.7803 mL
	30 mM	0.0593 mL	0.2967 mL	0.5934 mL	1.4836 mL
	40 mM	0.0445 mL	0.2225 mL	0.4451 mL	1.1127 mL
	50 mM	0.0356 mL	0.1780 mL	0.3561 mL	0.8902 mL
	60 mM	0.0297 mL	0.1484 mL	0.2967 mL	0.7418 mL
	80 mM	0.0223 mL	0.1113 mL	0.2225 mL	0.5564 mL

Brincidofovir Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

ブリンシドフォビル (Synonyms: Brincidofovir; CMX001; HDP-CDV)

カスタマーレビュー

Other Forms of Brincidofovir:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

HSV アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Brincidofovir Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

ブリンシドフォビル (Synonyms: Brincidofovir; CMX001; HDP-CDV)

カスタマーレビュー

Other Forms of Brincidofovir:

ブリンシドフォビル 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

HSV アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Brincidofovir Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

ブリンシドフォビル関連抗体